Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCL1 | Q07820 | 2/20 | 0.46 |
| ▸ | FAAH | O00519 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MMP1 | P03956 | 1/20 | 0.39 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | MMP3 | P08254 | 1/20 | 0.39 |
| ▸ | MMP9 | P14780 | 1/20 | 0.39 |
| ▸ | MMP8 | P22894 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5909428 | 0.88 | MCL1 (0.55) | MCL1FAAHMMP1MMP2MMP3 | |
| SCHEMBL2106440 | 0.82 | — | — | |
| SCHEMBL3318199 | 0.81 | FAAH (0.54) | MCL1FAAHLMNAMMP1MMP2 | |
| SCHEMBL169802 | 0.79 | MCL1 (0.50) | MCL1FAAHLMNAMMP1MMP2 | |
| SCHEMBL17407651 | 0.78 | MCL1 (0.46) | MCL1FAAHMMP1MMP2MMP3 | |
| SCHEMBL22095994 | 0.77 | FAAH (0.61) | MCL1FAAHLMNAKMT2AMAPT | |
| SCHEMBL28886374 | 0.77 | MCL1 (0.50) | MCL1FAAHMMP1MMP2MMP3 | |
| SCHEMBL14094896 | 0.76 | MCL1 (0.37) | MCL1LMNAMMP2MMP3MMP8 | |
| SCHEMBL28535342 | 0.76 | CTSD (0.50) | MCL1FAAHLMNAMMP1MMP2 | |
| SCHEMBL15616271 | 0.75 | MCL1 (0.40) | MCL1FAAHLMNAALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230321124-A1 | ROR gamma t Inhibitors and Topical Uses Thereof | DERMIRA, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230312825-A1 | POLYAMIDE-BASED FILM, MANUFACTURING METHOD THEREFOR, AND COVER WINDOW AND DISPLAY DEVICE EACH COMPRISING SAME | MICROWORKS SOLUTIONS CO., LTD. (KR) | 2023-10-05 | — | — | US | disclosed |
| US-20230183424-A1 | POLYAMIDE-IMIDE-BASED FILM, PREPARATION METHOD THEREOF, AND COVER WINDOW AND DISPLAY DEVICE COMPRISING THE SAME | MICROWORKS SOLUTIONS CO., LTD. (KR) | 2023-06-15 | — | — | US | disclosed |
| US-20180105606-A1 | ANTIBODIES TO QUETIAPINE HAPTENS AND USE THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2018-04-19 | — | — | US | disclosed |
| US-9850318-B2 | Antibodies to quetiapine haptens and use thereof | JANSSEN PHARMACEUTICA NV (BE) | 2017-12-26 | — | — | US | disclosed |
| US-20170343569-A1 | ANTIBODIES TO OLANZAPINE HAPTENS AND USE THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2017-11-30 | — | — | US | disclosed |
| US-20170240653-A1 | ANTIBODIES TO OLANZAPINE HAPTENS AND USE THEREOF | JANSSEN PHARMACEUTICA NV (BE) | 2017-08-24 | — | — | US | disclosed |
| US-20160194448-A1 | WINDOW FOR DISPLAY DEVICE AND DISPLAY DEVICE INCLUDING THE SAME | SAMSUNG SDI CO., LTD. (KR) | 2016-07-07 | — | — | US | disclosed |
| US-9304126-B2 | Haptens of quetiapine | JANSSEN PHARMACEUTICA NV (BE) | 2016-04-05 | — | — | US | disclosed |
| US-9303041-B2 | Haptens of olanzapine | JANSSEN PHARMACEUTICA NV (BE) | 2016-04-05 | — | — | US | disclosed |
| US-7854863-B2 | Functional materials for use in optical systems | BATTELLE MEMORIAL INSTITUTE (US) | 2010-12-21 | — | — | US | disclosed |
| US-7786298-B2 | Compounds and methods for nucleic acid mismatch detection | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2010-08-31 | — | — | US | disclosed |
| US-7579473-B2 | N-(4-{[7-{[3-(diethylamino)propyl] oxy}-6-(methyloxy) quinazolin-4-yl]oxy}-3- fluorophenyl)-N'-(4- fluorophenyl) cyclopropane-1,1-dicarboxamide; for modulating protein kinase enzymatic activity for modulating cell activities such as proliferation, differentiation, programmed cell death | EXELIXIS, INC. (US) | 2009-08-25 | — | — | US | disclosed |
| US-20090170896-A1 | c-Met modulators and methods of use | EXELIXIS, INC. (US) | 2009-07-02 | — | — | US | disclosed |
| US-20090015760-A1 | Method for manufacturing thin film transistors | HITACHI DISPLAYS, LTD. | 2009-01-15 | — | — | US | disclosed |
| US-20080161305-A1 | C-Met Modulators and Methods of Use | EXELIXIS, INC. (US) | 2008-07-03 | — | — | US | disclosed |
| US-20070244116-A1 | c-MET MODULATORS AND METHOD OF USE | EXELIXIS, INC. (US) | 2007-10-18 | — | — | US | disclosed |
| US-20070224612-A1 | Compounds and methods for nucleic acid mismatch detection | CALIFORNIA INSTITUTE OF TECHNOLOGY (US) | 2007-09-27 | — | — | US | disclosed |
| US-20070225307-A1 | C-MET MODULATORS AND METHOD OF USE | EXELIXIS, INC. (US) | 2007-09-27 | — | — | US | disclosed |
| US-20070054928-A1 | c-Met modulators and methods of use | EXELIXIS, INC. (US) | 2007-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070054928-A1 | c-Met modulators and methods of use | FLT4, FLT1, MET | MCL1 19/4885FAAH 4388/4885LMNA 2924/4885 |
| US-20180105606-A1 | ANTIBODIES TO QUETIAPINE HAPTENS AND USE THEREOF | HTR4, HTR3C, SLC6A4 | MCL1 2503/4885FAAH 1138/4885LMNA 3412/4885 |
| US-20070224612-A1 | Compounds and methods for nucleic acid mismatch detection | PCNA, ERCC4, MSH6 | MCL1 277/4885FAAH 4026/4885LMNA 730/4885 |
| US-20080161305-A1 | C-Met Modulators and Methods of Use | MET, HGFAC, HGF | MCL1 5/4885FAAH 4075/4885LMNA 3678/4885 |
| US-20170240653-A1 | ANTIBODIES TO OLANZAPINE HAPTENS AND USE THEREOF | HTR4, HTR3C, HTR1A | MCL1 2135/4885FAAH 877/4885LMNA 3224/4885 |
| US-20090170896-A1 | c-Met modulators and methods of use | FLT4, MET, FLT1 | MCL1 35/4885FAAH 4361/4885LMNA 3245/4885 |
| US-20230321124-A1 | ROR gamma t Inhibitors and Topical Uses Thereof | RORC, RORB, RORA | MCL1 2436/4885FAAH 2793/4885LMNA 4810/4885 |
| US-20070225307-A1 | C-MET MODULATORS AND METHOD OF USE | FLT4, MET, FLT1 | MCL1 47/4885FAAH 4338/4885LMNA 3308/4885 |
| US-20070244116-A1 | c-MET MODULATORS AND METHOD OF USE | FLT4, MET, FLT1 | MCL1 47/4885FAAH 4338/4885LMNA 3308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.